Systemic lupus erythematosus (SLE) is the form of the disease that most people are referring to when they say "lupus." The word "systemic" means the disease can affect many parts of the body. The symptoms of SLE may be mild or serious. Although SLE usually first affects people between the ages of 15 and 45 years, it can occur in childhood or later in life as well.
The U.S. Food and Drug Administration (FDA) this week provided the necessary authorization for clinical trials of chloroquine and hydroxychloroquine for the treatment of the novel coronavirus. These two drugs have been claimed by President Donald Trump to be a potential treatment for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, which causes COVID-19 disease. To date, there has been no conclusive proof regarding the safety and efficacy of these drugs in COVID-19 cases, say officials.
A new study published in the Journal of Investigative Dermatology reports that half the skin lesions present in patients with lupus show the presence of viable staph bacteria. This makes them more susceptible to skin infections and also increases the risk that the infection will spread to others.
A new trial involving the use of an antibody called anifrolumab reports improvement in patients with systemic lupus erythematosus (SLE) after 52 weeks of treatment. The research, titled 'Trial of Anifrolumab in Active Systemic Lupus Erythematosus', is published in the New England Journal of Medicine.
The American College of Rheumatology and the European League Against Rheumatism released the 2019 ACR/EULAR Classification Criteria for IgG4-Related Disease. It is the first criteria developed specifically for this recently recognized disease.
When it comes to cholesterol, we've come to accept a simple narrative. Our risk of heart disease is lower when we have more "good cholesterol," or high-density lipoproteins (HDL), and less "bad cholesterol," or low-density lipoproteins (LDL) and triglycerides.
Researchers have found that alteration in the environment and atomospheric factors could be associated with organ specific flare-ups of lupus among patients diagnosed with Systemic Lupus Erethematosus (SLE). The study results were presented at the 2019 ACR/ARP Annual Meeting. The abstract was titled, “Environmental and Atmospheric Factors in Systemic Lupus Erythematosus: A Regression Analysis.”
According to new research findings presented at the 2019 ACR/ARP Annual Meeting, adenosine deaminase 2 (ADA2) in the peripheral blood is a sensitive, specific biomarker for macrophage activation syndrome, a potentially life-threatening complication of systemic juvenile idiopathic arthritis (systemic JIA)
New research findings presented at the 2019 ACR/ARP Annual Meeting found a strong association between changes in atmospheric and environmental variables 10 days before a clinic visit and organ-specific lupus flares in patients with systemic lupus erythematosus.
Malaria is one of the world's deadliest infectious diseases: a small mosquito bite delivers numerous malaria parasites into the bloodstream. The human body defends itself valiantly against the parasite, which usually results in periodic flu-like symptoms and severe fever. Severe cases of the disease are accompanied by tissue damage and result in potentially fatal organ failure.
The immune system relies on B cells and their ability to make antibodies against an extremely broad range of pathogens. This broad responsiveness bears some risk, as B cells can also turn against healthy tissue - a phenomenon called autoimmunity.
The course of pregnancy, like that of true love, doesn’t always run smooth when you have lupus, correctly called systemic lupus erythematosus (SLE). This autoimmune disease is an occasionally violent, occasionally subdued, chronic inflammation that constantly smolders within multiple tissues in the body.
One of the important cells involved in the immune response is the T follicular helper (Tfh) cell. These are important in the normal process of antibody production following immunization, for instance. However, they are also abnormally increased in number in patients with autoimmune disease, such as systemic lupus erythematosus.
The body's immune response fights against infectious disease, and it safeguards against future infections through vaccination.
A breakthrough study by a SUNY Downstate Health Sciences University research team has identified a specific antibody target implicated in neuropsychiatric symptoms of lupus.
The team of researchers at the University of Houston found that blood clotting proteins, both the ones that promote blood clotting (prothrombic) and those that disperse them (thrombolytic) are elevated in the urine of patients with lupus nephritis (LN).
University of Houston researcher Chandra Mohan is reporting in Arthritis Research and Therapy that clotting proteins, both those that promote blood clots (pro-thrombotic) and those that work to dissipate them (thrombolytic), are elevated in the urine of patients who suffer from lupus nephritis (LN).
Systemic lupus erythematosus (SLE) is an autoimmune disease which was historically perceived to confer an unacceptably high risk to both mother and child during pregnancy. As a result, most women with the condition were counseled to avoid pregnancy or to terminate their pregnancy.
A team of researchers at the Emory University School of Medicine show that patients with SLE or lupus, have abnormal activation of B cells, which is part of the body’s immune system
New research on the autoimmune disease systemic lupus erythematosus provides hints to the origins of the puzzling disorder. The results were published in Nature Immunology.
Research supported by the Accelerating Medicines Partnership on Rheumatoid Arthritis and Systemic Lupus Erythematosus provides new insights into tissue damage for these autoimmune conditions.